Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Cytosorbents (CTSO) Tax Provisions (2016 - 2025)

Cytosorbents filings provide 12 years of Tax Provisions readings, the most recent being -$1000.0 for Q4 2025.

  • On a quarterly basis, Tax Provisions rose 99.94% to -$1000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$2.1 million, a 16.44% increase, with the full-year FY2025 number at -$401000.0, up 76.29% from a year prior.
  • Tax Provisions hit -$1000.0 in Q4 2025 for Cytosorbents, up from -$401000.0 in the prior quarter.
  • In the past five years, Tax Provisions ranged from a high of -$1000.0 in Q4 2025 to a low of -$1.7 million in Q4 2024.
  • Median Tax Provisions over the past 5 years was -$774871.0 (2021), compared with a mean of -$789221.2.
  • Biggest five-year swings in Tax Provisions: tumbled 107.81% in 2024 and later soared 99.94% in 2025.
  • Cytosorbents' Tax Provisions stood at -$736003.0 in 2021, then plummeted by 48.45% to -$1.1 million in 2022, then increased by 25.52% to -$813739.0 in 2023, then tumbled by 107.81% to -$1.7 million in 2024, then soared by 99.94% to -$1000.0 in 2025.
  • The last three reported values for Tax Provisions were -$1000.0 (Q4 2025), -$401000.0 (Q3 2025), and -$1.7 million (Q4 2024) per Business Quant data.